Clinicians at a Dermatology Times Case-Based Roundtable, moderated by Chesahna Kindred, MD, debated when to escalate to oral JAK inhibitors for alopecia areata and how to counsel patients on timing, ...

The American Academy of Dermatology (AAD) and Hidradenitis Suppurativa Foundation (HSF) have issued their first joint ...

Skin longevity is on a path to becoming a legitimate and consequential area of dermatology. For it to fully succeed, skin ...

Angela Fitch, MD, co-founder and chief medical officer of Knownwell, discussed GLP-1 access strategies and a proposed ...

This episode, "Efficacy and Safety Data for Emerging Oral HS Agents," has Chao presenting the latest trial results for ...

In "How Emerging Oral Therapies Target HS Inflammation," the panel explores how JAK and BTK inhibitors interrupt inflammation ...

Dermatology Times, Evidence-Based Cleansing and Moisturizing Practices for Protecting and Repairing the Skin Barrier, November 2025 (Vol. 46. Supp. 09) ...

Persistence and adherence, not efficacy claims alone, distinguish IL-23 biologics in practice. Real-world claims data reveal how administration setting and dosing interval shape whether older patients ...

At Fall Clinical 2026, Joel Gelfand, MD, MSCE, reviewed GLP-1 candidacy, weight conversations, and an upcoming monotherapy trial in psoriasis. A retrospective claims analysis of 2897 matched pairs ...

Angela Fitch, MD, co-founder and chief medical officer of Knownwell and past president of the Obesity Medicine Association, ...

Persistence and adherence, not efficacy claims alone, distinguish IL-23 biologics in practice. Real-world claims data reveal ...

At Fall Clinical 2026, Joel Gelfand, MD, MSCE, reviewed GLP-1 candidacy, weight conversations, and an upcoming monotherapy ...